Roth Capital upgraded shares of Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) from a neutral rating to a buy rating in a research note released on Tuesday morning, Marketbeat Ratings reports. The firm currently has $15.00 price target on the stock.

Several other research firms have also weighed in on ZYNE. Cantor Fitzgerald restated a buy rating and set a $28.00 price objective on shares of Zynerba Pharmaceuticals in a research note on Tuesday, May 9th. Canaccord Genuity set a $35.00 price objective on shares of Zynerba Pharmaceuticals and gave the stock a buy rating in a research note on Saturday, May 13th. Maxim Group set a $32.00 price objective on shares of Zynerba Pharmaceuticals and gave the stock a buy rating in a research note on Monday, June 26th. Zacks Investment Research upgraded shares of Zynerba Pharmaceuticals from a sell rating to a hold rating in a research note on Thursday, July 13th. Finally, BidaskClub upgraded shares of Zynerba Pharmaceuticals from a sell rating to a hold rating in a research note on Wednesday, July 12th. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating and two have given a buy rating to the company’s stock. The stock currently has an average rating of Hold and a consensus target price of $12.67.

Shares of Zynerba Pharmaceuticals (ZYNE) opened at 6.25 on Tuesday. The firm’s 50-day moving average is $14.21 and its 200-day moving average is $18.65. The company’s market capitalization is $82.86 million. Zynerba Pharmaceuticals has a 12-month low of $5.42 and a 12-month high of $25.95.

Zynerba Pharmaceuticals (NASDAQ:ZYNE) last released its quarterly earnings data on Tuesday, August 1st. The company reported ($0.64) earnings per share for the quarter, missing the consensus estimate of ($0.60) by $0.04. On average, equities research analysts anticipate that Zynerba Pharmaceuticals will post ($2.45) EPS for the current fiscal year.

WARNING: This report was first published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this report on another site, it was illegally stolen and reposted in violation of United States & international copyright & trademark laws. The legal version of this report can be viewed at https://theolympiareport.com/2017/08/19/zynerba-pharmaceuticals-inc-zyne-upgraded-to-buy-at-roth-capital.html.

Several hedge funds have recently made changes to their positions in ZYNE. Nationwide Fund Advisors bought a new stake in shares of Zynerba Pharmaceuticals during the second quarter valued at approximately $110,000. The Manufacturers Life Insurance Company bought a new stake in shares of Zynerba Pharmaceuticals during the second quarter valued at approximately $158,000. FNY Managed Accounts LLC bought a new stake in shares of Zynerba Pharmaceuticals during the first quarter valued at approximately $180,000. SG Americas Securities LLC bought a new stake in shares of Zynerba Pharmaceuticals during the first quarter valued at approximately $188,000. Finally, New York State Common Retirement Fund bought a new stake in shares of Zynerba Pharmaceuticals during the second quarter valued at approximately $207,000. 26.74% of the stock is owned by institutional investors and hedge funds.

Zynerba Pharmaceuticals Company Profile

Zynerba Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing transdermal synthetic cannabinoid treatments for patients with high unmet needs. Its development pipeline includes two product candidates: ZYN002 and ZYN001. ZYN002 is a synthetic cannabidiol (CBD), which is a non-psychoactive cannabinoid, formulated as a patent-protected permeation-enhanced gel for transdermal delivery through the skin and into the circulatory system.

Analyst Recommendations for Zynerba Pharmaceuticals (NASDAQ:ZYNE)

Receive News & Ratings for Zynerba Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynerba Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.